Introduction The aim of our study was to systematically review the growing body of published
literature reporting on one specific multiple sclerosis (MS) treatment, fingolimod, in the real …

Introduction In recent years, many treatment options have become available for relapsing
remitting MS. Randomized clinical trials and real-world studies are complementary sources …

Fingolimod approval was based mainly on two clinical trials, FREEDOMS and
TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with …

Background Fingolimod was approved and reimbursed by the healthcare provider in
Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in …

Abstract Background and Objective Once-daily oral fingolimod is approved in the EU as
escalation treatment for adult patients with highly active relapsing multiple sclerosis (MS) …

Background Cerebral gray matter (GM) atrophy has clinical relevance in multiple sclerosis
(MS). Fingolimod has known efficacy on clinical and conventional MRI findings in MS; the …

Background Fingolimod is approved for the treatment of highly active relapsing–remitting
multiple sclerosis in Europe. There is limited information on its effectiveness and safety in …

Introduction: The primary aim of the present study was to evaluate the long-term efficacy of
fingolimod in patients with multiple sclerosis (MS); secondary aims were to describe the …

Background Follow-on disease modifying therapies (FO-DMTs) do not always require Phase
III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare …

Macular oedema is a known side effect to fingolimod, but changes in specific areas of the
retina are only sparsely described. Our aim was to investigate the prevalence of macular …